Excellence in Dermatology™
Excellence in Dermatologic Surgery™
Excellence in Medical Dermatology™
Excellence in Dermatopathology™

F023 - Atopic Dermatitis

Friday, February 16; 1:00 PM - 3:00 PM

Learning Objectives

Following this course, the attendee should be able to:

  • Recognize advances in understanding of pathogenesis of atopic dermatitis
  • Formulate best practices in patient and family education and counseling
  • Improve knowledge of traditional and emerging topical and systemic therapies

Description

Effectively treating patients with atopic dermatitis yields great rewards for patients, families and providers. This session reviews advances in our understanding of the pathobiology of the disease, reviews treatment guidelines and informs providers of the emerging systemic therapies on the horizon. Discussions of therapeutics will extend beyond treatment guidelines as experienced clinicians will share their treatment pearls they find useful in their toughest pediatric and adult patients.

Disclosures

  • Eichenfield, Lawrence F., MD: Allergan, Inc – C(H), I(Fees); Anacor Pharmaceuticals, Inc. – C(H); Cutanea Life Sciences – C(H); Dr. Reddy – C(H); DS Laboratories – C(H); Elsevier Inc. – O(IP); Galderma Laboratories, L.P. – C(H), I(Fees); Genentech, Inc. – C(H); Kimberly Clark – I(Fees); LEO Pharma, US – C(H), I(Fees); Lilly ICOS LLC – C(H); Medimetriks Pharmaceuticals, Inc. – C(H); Novan – C(H), I(Fees); Otsuka Pharmaceutical Co., Ltd. – C(H); Pfizer Inc. – C(H); Ralexar Therapeutics, Inc – C(H); Sanofi/Regeneron – C(H), I(Fees); Tioga Pharmaceuticals, Inc. – C(H); TopMD – C(SO); Valeant Pharmaceuticals International – C(H); Valeant Pharmaceuticals North America LLC – I(Fees); Wiley-Blackwell – O(H);
  • Guttman, Emma, MD, PhD: AbbVie – C(H); Allergan, Inc. – C(H); Almirall – C(H); Anacor Pharmaceuticals, Inc. – C(H); Asana Biosciences, LLC – C(H); Celgene Corporation – A(H), C(H), I(Grants/Research Funding); Dermira – A(H), C(H); Eli Lilly and Company – C(H), I(Grants/Research Funding); Escalier – C(H); Galderma Research & Development, LLC – A(H), C(H); Glenmark Generics Inc. – B(H), C(H), I(Grants/Research Funding); Janssen Pharmaceuticals, Inc – I(Grants/Research Funding); Kyowa Hakko Kirin Pharma, Inc. – C(H); Leo Pharma Inc – C(H), I(Grants/Research Funding); Medimmune – A(H), C(H), I(Grants/Research Funding); Novartis – A(H), C(H), I(Grants/Research Funding); Pfizer Inc. – A(H), C(H); Regeneron – A(H), C(H); Regeneron Pharmaceuticals, Inc. – I(Grants/Research Funding); sanofi-aventis – C(H); Sanofi/Regeneron – B(H); Stiefel a GSK company – C(H); Theravance Biopharma – C(H); Vitae Pharmaceuticals – C(H), I(Grants/Research Funding);
  • Lio, Peter A., MD: AbbVie – C(Fees); Anacor Pharmaceuticals, Inc. – A(H); AOBiome, LLC – I(Grants/Research Funding); DermTap, Inc. – A(SO); Exeltis – C(Fees); Ferndale Laboratories, Inc. – SP(H); Franklin BioScience – C(SO); Galderma Laboratories, L.P. – SP(Fees); Galderma Laboratories, LP – C(Fees); Heel (Biologische Heilmittel Heel GmbH) – C(Fees); IntraDerm Pharmaceuticals – A(H); Johnson & Johnson Consumer Products Company – A(H), C(Fees), SP(Fees); Kiniksa Pharmaceuticals, Ltd. – I(Grants/Research Funding); L'Oreal USA Inc. – C(H); La Fondation pour la Dermatite Atopique (Foundation for Atopic Dermatitis – I(Grants/Research Funding); La Roche-Posay Laboratorie Pharmaceutique – SP(H); Menlo Therapeutics – A(H); Mission – Speaker/Faculty Education(H); Modernizing Medicine – A(NC), SH(SO); National Eczema Association – A(NC); Odeza LLC – C(SO); Pfizer Inc. – SP(H); Pierre Fabre Dermatologie – SP(H); Realm Therapeutics – A(H); Regeneron – A(Fees), SP(Fees); Sanofi US Services – A(H); Syncere Skin Systems – A(SO); Theraplex – C(Fees); Valeant Pharmaceuticals International – C(Fees); Valeant Pharmaceuticals North America LLC – SP(H);
  • Paller, Amy S., MD: AbbVie – I(NC); Amgen – C(H), I(NC); Amicus Therapeutics – C(H); BridgeBio Pharma, LLC – A(H); Castle Creek Pharmaceuticals – C(H); Celgene Corporation – I(NC); Dermira – C(H); Eli Lilly and Company – C(H); Expanscience – Speaker/Faculty Education(H); Galderma Laboratories, L.P. – C(H); Janssen Pharmaceuticals, Inc – I(NC); Leo Pharma Inc – I(Grants/Research Funding); Menlo Therapeutics – A(H); Novartis Pharmaceuticals Corp. – C(H); Pfizer Inc. – C(H); Regeneron – C(H); Sanofi/Regeneron – A(H); Stiefel a GSK company – C(H); Valeant Pharmaceuticals North America LLC – C(H);
  • Simpson, Eric Lawrence, MD: AbbVie – C(Fees); Eli Lilly and Company – I(Grants/Research Funding); GlaxoSmithKline – C(Fees); Medimmune – I(Grants/Research Funding); Novartis – I(Grants/Research Funding); Pfizer Inc. – C(Fees), I(Grants/Research Funding); Regeneron – C(Fees), I(Grants/Research Funding); Roivant Sciences – I(Grants/Research Funding); Tioga Pharmaceuticals, Inc. – I(Grants/Research Funding); Vanda Pharmaceuticals Inc. – I(Grants/Research Funding);
Event Details
  • Date
    Friday, February 16
  • Time
    1:00 PM - 3:00 PM
  • Location
    Ballroom 20B
  • CME Credits
    2.00
  • Type
Directors/Co-Directors
  • Eric Lawrence Simpson, MD, FAAD
  • Lawrence F. Eichenfield, MD, FAAD
Speakers
  • Amy S. Paller, MD, FAAD - Handout
  • Emma Guttman, MD, PhD, FAAD - Handout
  • Peter A. Lio, MD, FAAD